Mario David Saltarelli
Director/Board Member at BIOASIS TECHNOLOGIES INC.
Net worth: - $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Deborah Rathjen | M | - | 7 years | |
| Reshma Kewalramani | M | 51 | 7 years | |
| Jean-Paul Kress | M | 59 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 6 years |
| Mark Tyndall | M | 48 | 10 years | |
| Ian John Massey | M | 73 |
GABA Therapeutics, Inc.
 GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
| David Wurzer | M | 65 | 6 years | |
| Richard Gregory Farrell | M | - |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
| Christopher Lowe | M | 56 | 7 years | |
| John E. Curran | M | - | 6 years | |
| Alan Garber | M | 68 | 7 years | |
| Nathan Dowden | M | 54 | 5 years | |
| Leslie Waltke | F | - | 12 years | |
| John Hemeon | M | 59 | - | |
| Mei Mei Tian | M | - | 12 years | |
| H. Christian Fibiger | M | 80 |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
| Florian Brand | M | 37 |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
| Graeme Dick | M | - | 13 years | |
| Nia Tatsis | M | 54 | 7 years | |
| Stephanie Franklin | F | - | 7 years | |
| Matthias Luz | M | - |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
| Dave Jenkins | M | - | 3 years | |
| Jared Cohen | M | - | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Angus Russell | M | 68 | 23 years | |
| Susan Kilsby | F | 65 | 8 years | |
| David de Graaf | M | - |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| Mark Day | M | 52 | 2 years | |
| Sandra L. Hatten | F | 67 | 5 years | |
| Joshua Boger | M | 73 | 28 years | |
| Don Bailey | M | 78 | 2 years | |
| Ian Karp | M | - | 5 years | |
| Mahalakshmi Radhakrishnan | M | - | 1 years | |
| Nancy E. Stagliano | M | 57 | 2 years | |
| Flemming Ørnskov | M | 66 | 6 years | |
| Carole Nüchterlein | F | 62 | 3 years | |
| John Crowley | M | 57 | 4 years | |
| Caroline Dircks | M | - | 2 years | |
| Hugh M. Oneill | M | 60 | 9 years | |
| Jeffrey Chodakewitz | M | 68 | 4 years | |
| Steven Gillis | M | 71 | 7 years | |
| Virgil Thompson | M | 84 | - | |
| Brendan St Amant | M | - | 2 years | |
| Christine Antalik | F | 53 | 2 years | |
| G. Michael Palladino | M | - | 8 years | |
| Dawn M. von Rohr | F | - | 21 years | |
| John Yee | M | - | 2 years | |
| Karen Sheehy | F | 62 | - | |
| Jill Quigley | F | 49 | 4 years | |
| Laura Gault | F | - | 2 years | |
| Craig Hopkinson | M | 56 | 3 years | |
| Leslie Stolz | M | 52 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| Adam Hansard | M | 48 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 1 years |
| Laura Sepp-Lorenzino | M | 63 | 2 years | |
| Antoinette Paone | F | 46 | 12 years | |
| Matthew Mainer | M | 53 | 1 years | |
| Kimberly A. White | F | - | - | |
| Thomas Englese | M | 50 | 4 years | |
| Debra Silberg | M | - | - | |
| Jeffrey Patrick | M | 55 | 4 years | |
| Joanne Cordeiro | F | 66 | 8 years | |
| Aaron Kantoff | M | 29 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 4 years |
| Thomas Graney | M | 59 | 1 years | |
| Barbara H. Deptula | F | 69 | 8 years | |
| Steve Cartt | M | 61 | - | |
| Suzanne Bruhn | M | 60 | 14 years | |
| Stephen Merrick | M | 63 | - | |
| Frank Scholz | M | 54 | 5 years | |
| Jeffrey Leiden | M | 68 | 6 years | |
| Burt Adelman | M | 71 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | 2 years |
| Kevin Rakin | M | 63 | 1 years | |
| Steven Romano | M | 64 | 7 years | |
| Michael Mulroy | M | 58 | - | |
| Peter Edwards | M | 62 | 5 years | |
| Perry Sternberg | M | 55 | 6 years | |
| Mark Enyedy | M | 60 | 3 years | |
| May Orfali | M | - | - | |
| Thomas Smith | M | 63 | 2 years | |
| Andrew Cheng | M | 57 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| Jodie Morrison | F | 48 |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | - |
| Dawn Kalmar | F | 47 | 8 years | |
| Gary Phillips | M | 58 | - | |
| Raymond Furey | M | 56 | - | |
| Ann Powell | F | 58 | 4 years | |
| Arthur Tzianabos | M | 60 | 8 years | |
| MARIA V BRESNAHAN | M | - | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 48 | 57.14% |
| Ireland | 36 | 42.86% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mario David Saltarelli
- Personal Network
